BioMed Research International / 2013 / Article / Tab 1

Research Article

Off-Label Use of Ondansetron in Pregnancy in Western Australia

Table 1

Maternal characteristics of women dispensed ondansetron any time during pregnancy.

Ondansetron
  
 Nonondansetron
   = 96,447
OR (95% CI)
% %

Caucasian23894.881,88884.93.3 (1.9–5.7)
Did not smoke during pregnancy23493.279,73182.82.9 (1.8–4.7)
Parity > 117770.567,26769.71.0 (0.8–1.4)
Multiple birth114.41,5851.62.7 (1.5–5.0)
Privately insured19577.736,01237.35.8 (4.3–7.9)
Not single24598.087,65491.34.7 (1.9–11.4)
Previous preterm delivery105.65,5898.30.7 (0.3–1.3)
SEIFA
 <25%2110.019,03824.71
 25–50%4024.519,32228.81.9 (1.1–3.2)
 50–75%8853.329,34737.92.7 (1.7–4.4)
 >75%8636.618,98121.94.1 (2.5–6.6)
Labour and delivery characteristics
 Threatened preterm labour, <37 wks*93.62,2672.42.3 (1.0–4.9)
 Preterm birth, <37 wks*3413.57,8728.21.4 (0.7–2.5)
 Obstetrician at delivery**18372.939,39940.91.7 (1.2–2.4)
 Epidural/caudal anaesthetic16766.545,27246.92.2 (1.7–2.9)
 Caesarean11144.230,94732.11.7 (1.3–2.2)
 Previous Caesarean5220.713,20413.71.7 (1.2–2.4)
 Elective Caesarean**7630.317,51018.21.3 (1.0–1.8)
 Emergency Caesarean3513.913,43813.91.0 (0.7–1.4)
 Postpartum haemorrhage 500 mls***187.28,8449.21.2 (0.7–2.0)
 Induced labour8734.728,47529.61.3 (1.0–1.6)
 Threatened abortion, <20 wks156.04,9645.11.2 (0.7–2.0)
 Analgesia provided11244.635,28936.61.4 (1.1–1.8)
 Artificial rupture of membranes7529.922,21323.01.4 (1.1–1.9)
Pregnancy characteristics
 Admitted to hospital for HG**8835.11,6461.732.8 (25.1–42.9)
 Fertility treatment114.42,3402.41.8 (1.0–3.4)
 Urinary tract infection135.23,2513.41.6 (0.9–2.7)
 Preeclampsia176.84,3434.51.5 (0.9–2.5)
 Amniocentesis93.62,5732.71.4 (0.7–2.6)
 Other complications of pregnancy9638.218,78219.52.6 (2.0–3.3)

Adjusted for previous preterm birth, maternal age, smoking during pregnancy, SEIFA, parity, private health insurance, and multiple birth.
**Adjusted for private health insurance and multiple birth.
***Adjusted for Caesarean delivery, private health insurance, and multiple birth.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.